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Rapid COVID-19 diagnosis in hospital is essential, though complicated by 30-50% of 
nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing 
(NAAT). Furthermore, the D614G spike mutant now dominates the pandemic and it is 
unclear how serological tests designed to detect anti-Spike antibodies perform against this 
variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) 
and nucleic acid assays for suspected COVID-19 disease due to either wild type or the 
D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95CI 
57.8-92.9%) by rapid NAAT alone. Combined point of care antibody test and rapid NAAT is 
not impacted by D614G and results in very high sensitivity for COVID-19 diagnosis with 
very high specificity. 
  
Introduction 
As of the 2nd of August 2020, more than 18.0 million people have been infected with SARS-
CoV-2 with over 690,000 deaths1. The unprecedented numbers requiring SARS-CoV-2 
testing has strained healthcare systems globally. There is currently no gold standard for 
diagnosis of COVID-19. Detection of SARS-CoV-2 by nucleic acid amplification testing 
(NAAT) is largely done by real time RT-PCR on nose/throat swabs in centralised 
laboratories. RT-PCR specimens are often batch analysed and the turnaround time for this 
test can be as long as 2- 4 days in real world settings2. NAAT tests from a single nose/throat 
swab are negative in up to 50% in patients who have CT changes consistent with COVID-19 
and/or positive antibodies to SARS-CoV-2 3-5. The lack of detectable virus in upper airway 
samples is not only a serious barrier to making timely and safe decisions in the emergency 
department, but also leads to multiple swab samples being sent, frequently from the same 
anatomical site, leading to additional strain on virology laboratories. Nonetheless, NAAT 








tracheo-bronchial samples might be NAAT positive even when the nose/throat swab is 
negative4,6.  
 
Multiple factors might contribute to negative results by NAAT, including test sensitivity, 
sampling technique and timing of the sampling in the disease course6. The viral load in the 
upper respiratory tract is detectable from around 4 days before symptoms7 and frequently 
wanes after a week post symptom onset8 9. Similarly, a case series from Germany found the 
detection rate by RT-PCR was <50% after 5 days since onset of illness10. A proportion of 
patients develop a secondary deterioration in clinical condition requiring hospitalisation and 
respiratory support, at a time when immune pathology is thought to be dominant rather than 
direct pathology related to viral replication 9,11.  
 
An antibody response to SARS-CoV-2 is detectable 6 days from infection and is almost 
always neutralising 12,13. Antibody based diagnosis of COVID-19 shows increasing 
sensitivity in the latter part of the infection course when NAAT testing on nose/throat 
samples is more likely to be negative14-17. As a result, diagnosis of infection as well as 
identification of infectivity would benefit from a combination of virologic and immunologic 
markers to inform patient initial triage and subsequent management. It is critical to determine 
whether a rapid point of care combined antibody and nucleic acid testing strategy could 
improve diagnosis. 
 
We previously evaluated the diagnostic accuracy of the SAMBA II SARS-CoV-2 rapid test 
compared with the standard laboratory RT-PCR and found similar accuracy with a 
turnaround time of 2-3 hours even in real world settings 18. Several studies have now reported 
head-to-head comparisons of immuno-chromatographic lateral flow immunoassays (LFAs)15-
17,19
. These assays are cheap to manufacture and give a binary positive/negative result, 
thereby lending themselves well to point of care (POC) testing. Even though they have 
variable performance and in general are negative in the early phase of infection, they become 
highly sensitive in the later stage of illness15-17,19 and some are also highly specific.  
 
In this study we evaluated the diagnostic performance of a POC combination comprising 
NAAT and antibody testing against a composite reference standard of laboratory RT-PCR 
and a serum neutralisation assay. Notably, SARS-CoV-2 viruses with a D to G mutation in 








D614 may play a role in Spike inter-molecular stability 21, potentially contributing to 
increased infectivity 20. Given POC antibody tests were designed to detect antibodies to wild 
type S protein, we also aimed to investigate whether SARS-CoV-2 infections with D614G 
Spike mutant virus could be diagnosed by POC antibody tests. 
 
Results  
In phase one, 45 prospectively recruited participants in the COVIDx study with suspected 
COVID-19 disease had nose/throat swabs specimens tested for nucleic acid as well as stored 
sera for antibody testing. Samples at hospital admission were collected at a median of 7 (IQR 
7-13) days after illness onset. The sera from 42.2% (19/45) participants showed neutralising 
antibody response against SARS-CoV-2 Spike protein pseudotyped virus infection in a 
neutralisation assay using a cut-off of 50% inhibition at 1:4 dilution (Figure 1A). 26 
participants’ sera showed no neutralising response (Figure 1B). The neutralisation ability of 
participants’ sera was compared with an in house ELISA IgG assay for Spike specific 
antibodies based on a recently reported method22 (Supplementary Figure 1), and significant 
association between positive results in both assays was demonstrated (Figures 1C, p<0.0001). 
Figures 1D-G shows significant associations between the point of care antibody test result 
and both ELISA (p<0.0001) and neutralisation assays, p<0.0025. POC antibody testing 
showed no cross reactivity in sera obtained before the pandemic (Supplementary table 1). 
The neutralisation assay also demonstrated lack of cross-reactivity with SARS-CoV-1 on a 
limited subset of sera (Supplementary Figure 2).  
 
Results from the four IgG antibody assays utilised in this study were confirmed (4 or 3 
concordant) in 38/45 samples and, against this classification, neutralisation (Figure 1A-C), 
spike ELISA (22 Figure C,D,F and Supplementary Figure 1), Surescreen and COVIDIX 
Healthcare assays gave a correct result in 100%, 97.4%, 92.1% and 86.8%, respectively, 
justifying the choice of the neutralisation assay as part of a composite reference standard.  
 
53.3% (24/45) of participants had COVID-19 disease, as determined by the composite 
reference standard (lab RT-PCR and neutralisation assay). Median age was 73.5 (IQR 54.0-
86.5) years in those with SARS-CoV-2 infection by our composite reference standard and 
63.0 (IQR 41.0-72.0) years in those without disease (Table1). CRP and procalcitonin were 
significantly higher in confirmed COVID-19 patients and ‘classical’ chest radiograph 








However, 6/24 (25%) had normal or indeterminate chest radiographs in the confirmed 
COVID-19 group.  
 
As expected from the clinical study inclusion criteria, more than 80% of patients presented 
with influenza like illness (ILI) with documented fever and approximately one third had 
clinical or radiological evidence of pneumonia (Table 1). Highly experienced internal 
medicine physicians were caring for suspected COVID-19 cases at our institution, and this 
was partly due to the significant co-morbidities in the local population that mandated a broad 
differential diagnostic approach in hospitalised individuals (Table 1). Amongst patients with 
COVID-19 one suffered from rheumatoid arthritis and was currently immunosuppressed with 
Prednisolone. Amongst patients without COVID-19, five were immunosuppressed for the 
following conditions: psoriatic arthritis - Usekinumab (anti IL-12, IL-23); multiple myeloma 
- Lenalidomide and dexamethasone; Lymphoma – ciclosporin; hypersensitivity pneumonitis - 
mycofenalate and prednisolone; renal transplant - mycofenalate and tacrolimus. No patients 
in the study were under treatment with the anti-B cell monoclonal antibody rituximab. 
 
During the peak of the first wave routine respiratory virus testing was halted at our institution 
due to the demands of SARS-CoV-2 testing and low seasonal prevalence of these pathogens. 
Multiplex PCR for other respiratory viral pathogens was performed in only 8 participants. 
Seven of these participants were negative and one participant tested positive for influenza A.  
 
The overall COVID-19 diagnosis rate (positive predictive agreement) by rapid nucleic acid 
testing was 79.2% (95% CI 57.8-92.9), decreasing from 100% (95% CI 65.3-98.6%) for days 
1-4 to 50.0% (95% CI 11.8-88.2) for days 9-28 post symptom onset (Table 2 and 
Supplementary Figure 3). When IgG/IgM rapid tests were combined with NAAT, the overall 
positive predictive agreement increased to 100% (95% CI 85.8-100) (Table 2). Additional 
cases of COVID-19 detected in NAAT negative patients were identified by POC tests under 
investigation (Figure 2). Among 21 COVID-19 negative individuals, there were three false 
positive results for one POC antibody test and one false positive result for the other, resulting 
in positive predictive values of 88.9% and 96.0% for the two POC antibody/ SAMBA II 
NAAT combinations. 
 
Those with positive NAAT and sequence available were predominantly infected with strains 








located on the Spike surface (Figure 3A, B). 14/24 (58.3%) patients deemed to be COVID-19 
positive by the reference composite standard were positive by both rapid NAAT and antibody 
testing and 14/14 were infected with strains bearing D614G, indicating that point of care 
serological tests were able to detect infections with this variant.  
 
To understand the relationship between POC band intensity and neutralisation activity 
further, we identified three participants (all infected with D614G Spike mutant) with stored 
samples at multiple time points in their illness (Figure 4). Two individuals were sampled 
from early after symptom onset and the third presented three weeks into illness. In the first 
two cases (Figure 4A-F), we observed an increase in neutralisation activity over time that was 
mirrored by band intensities on rapid POC antibody testing. As expected IgM bands arose 
early on with IgG following closely. Of note in patient 1 there was a weakly detectable IgM 
band by rapid test with no serum neutralisation activity (Figure 4A, B). Over time the band 
intensity for IgM and IgG increased along with serum neutralisation activity. In the 
individual presenting 21 days into illness (Figure 4G-I), only IgG was detected with rapid 
POC antibody testing and as expected band intensity did not increase over the following 
days.  
 
In phase 2, we performed a prospective evaluation of combined testing in 128 patients 
presenting with possible COVID-19 from July 13th to 27th 2020. Their clinical presentation 
was less severe and diagnoses broader than in phase 1 (Table 3), with cardiovascular and 
gastrointestinal disease significantly represented and respiratory disease representing just 
60% of cases - likely as a result of the increased appreciation of diverse presentations of 
COVID-19 disease 23. Patients did have significant comorbidities and around 10% were 
immune suppressed, though without B cell depleting agents (Table 3). By this time the POC 
NAAT test had been validated in a head to head study against the lab RT-PCR and entered 
routine use (Collier et al., 2020), replacing the RT-PCR. Given the need to further assess the 
specificity of the POC antibody tests in routine clinical practice and with fresh blood rather 
than serum, we compared the performance of POC antibody tests on finger prick blood 
against serum neutralisation (Figure 5A and B).  
 
In this second phase there was only one NAAT positive case, who was also positive by both 
POC antibody tests and serum neutralisation. There were three NAAT negative individuals 








COVIDIX and SureScreen, along with serum neutralisation activity. The POC antibody tests 
showed 100% negative predictive agreement with serum neutralisation and the kappa 




Here we have shown that POC NAAT testing in combination with antibody detection can 
significantly improve diagnosis of COVID-19. Overall positive predictive agreement against 
the composite reference standard under clinical trial conditions was around 79% for rapid 
NAAT testing of nose/throat swab samples, reaching 100% with a combined approach of 
rapid NAAT testing and either of the two POC lateral flow-based antibody tests. The 
specificity of the combined approach was 85-95% on stored serum under clinical trial 
conditions and 100% on fingerprick blood in routine clinical care. 
 
As expected, nucleic acid detection in nose/throat samples was highest in those presenting 
within the first few days (100% in samples taken in the first 4 days after symptom onset). 
Conversely antibody detection by LFA increased with time since symptom onset with 100% 
efficacy beyond 9th day post-symptoms. One study reported that combined lab based RT-
PCR with lab based antibody testing could increase sensitivity for COVID-19 diagnosis from 
67.1% to 99.4% in hospitalised patients24. However, in that study this assessment of 
sensitivity was made using clinical diagnosis. A major strength of this study is the use of an 
objective reference standard that included NAAT and serum neutralisation - a phenotypic test 
for functionality of antibodies. This assay was shown to be robust and accurate, using a 
recently described ELISA method for SARS-CoV-2 IgG detection that is now used 
globally22.  
 
The D614G Spike mutant has spread globally. Wild type Spike protein antigen is used in the 
development and validation of POC antibody tests, including those tested here. Of critical 
importance is the fact that both POC antibody tests (and ELISA) were able to detect antibody 
responses in patients infected with the D614G Spike mutant and that band intensity of POC 
testing increased with neutralisation activity in these individuals. Given that POC antibody 
tests are far cheaper and simpler to deploy, they will likely be used in low resource settings 
that do not have access to NAAT25. Demonstration that POC antibody LFA tests can detect 








 Use of antibody tests for COVID-19 diagnosis in hospitals has been limited for a number of 
reasons. Firstly, we know from SARS-CoV-1 that previous humoral immunity to HCoV 
OC43 and 229E can elicit a cross-reactive antibody response to N of SARS-CoV-1 in up to 
14% of people tested in cross-sectional studies26, and previous exposure to HCoV can rarely 
elicit a cross-reactive antibody response to the N and S proteins of SARS- CoV-2 16,27. 
Secondly, antibody tests do not achieve the same detection rates as nucleic acid based tests 
early in infection, as humoral responses take time to develop following viral antigenic 
stimulation. However, by day 6 post symptom onset detection of IgG to Spike protein has 
been reported to reach 100% sensitivity 12 and this is useful in cases with immune mediated 
inflammatory disease where RT-PCR on respiratory samples is often negative, for example in 
the recently described Kawasaki-like syndrome named PIMS (paediatric inflammatory multi-
system syndrome) 28.  
 
In phase one (COVIDx trial) we tested stored sera rather than whole blood finger prick, 
though this was intentional given the caution needed in interpreting LFAs and concern 
regarding potential cross-reactivity of antibodies and poor specificity. Although SARS-CoV-
2 ELISA testing of our pre-pandemic sera did reveal occasional N reactivity to SARS- CoV-
2, likely due to cross reactivity with seasonal CoV, these samples were negative on POC 
antibody testing. However, the specificity of the COVIDIX test was estimated at only 85%, 
compared to a more acceptable 95% for SureScreen. We therefore carried out prospective 
evaluation of POC antibody testing on finger prick blood in 128 suspected cases of COVID-
19 in order to further evaluate specificity of both tests in routine clinical practice. We found 
no false positives in patients whose sera were non-neutralising. This is consistent with an 
estimated specificity of above 99% with the SureScreen assay observed in an independent 
analysis using stored pre-pandemic sera29. The greater incidence of false positive POC 
antibody tests, predominantly with COVIDIX, on stored sera as compared to fresh finger 
prick blood may be due to processing and storage of sera, contamination of sera with other 
blood products, or other causes, including patient factors that differed between the two 
phases. Nevertheless, now that we are in a low incidence period it is advisable to perform 
confirmation testing using an alternative platform for either a single positive antibody or 
NAAT test, as is now the policy at our institution. One should note in particular that antibody 
tests may be negative in patients with immune suppression, highlighting that patient factors 








 We envisage a deployment approach whereby both test samples, finger prick whole blood 
and nose/throat swab, are taken at the same time on admission to hospital. The finger prick 
antibody test result is available within 15 minutes. Due to the possibility of false positive 
results from POC serology testing, a positive POC antibody test result as the only positive 
marker should ideally be confirmed with a second rapid POC test / laboratory IgG/IgM test 
before movement to a COVID-19 area, or recruitment into a clinical treatment study. At our 
institution further diagnostic data from chest imaging and blood indices such as lymphocyte 
count and C-reactive protein when assessing patients for COVID-19 and clinical decision 
making. Further swabs for NAAT testing are also taken where possible.  
 
A confirmed positive NAAT result remains critical not only to identify early infection but, 
more importantly to triage infectious patients to be isolated from other patients and be 
handled with particular care by staff. NAAT is also valuable in milder and asymptomatic 
cases given severity appears to correlate with magnitude of antibody responses 16,30. In 
conclusion rapid combined testing could be important in diagnosis and management of 
COVID-19, particularly given the pandemic is not well controlled in many parts of the world 
and as diverse manifestations of disease emerge. 
 
Limitations of study 
This study was limited by the fact that it was conducted at a single centre with relatively 
small numbers of individuals in the clinical study (phase 1), largely due to a lack of available 
stored serum. Phase 1 of the study used stored serum where there was a higher false positive 
rate than phase 2 where whole blood was used. The implementation study (phase 2) had 
greater numbers and was able to effectively demonstrate the high specificity of POC antibody 
tests and very low false positive rate for both POC antibody tests on whole blood, though 
itself was hampered by the low incidence of COVID-19 infection during the period it was 
undertaken. This low incidence rate in phase 2 limited further evaluation of the sensitivity of 
the combined approach. There was also a lack of data on repeated sampling and sampling 
from deeper respiratory sites in those suspected cases who were NAAT negative. Future 
larger studies are warranted.  
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Table 1: Characteristics of participants in diagnostic accuracy study. COVID-19 status is 
based on composite reference standard test of nose/throat swab SARS-CoV-2 RT-PCR + 
serum neutralisation of pseudovirus bearing SARS-CoV-2 Spike. § Wilcoxon rank sum test 
used except where indicated. a Chi-square test. 
 




P value § 
Male sex (%) 14 (58.3) 9 (42.9) 0.30a 
Median age (IQR) years 73.5 (54.0-86.5) 63.0 (41.0-72.0) 0.03 
Influenza-like illness with 
documented fever 
20 (83.3) 17 (81.0) 0.84 
Clinical or radiological evidence of 
pneumonia 
10 (41.7) 7 (33.3) 0.57 
Immunosuppressed 
   Yes 










Cardiovascular disease 6 (25.0) 2 (9.5)  0.25 
Chronic Respiratory disease 5 (20.8) 6 (28.6) 0.73 
Chronic Renal disease 4 (16.7) 2 (9.5) 0.67 
Diabetes Mellitus 6 (25.0) 3 (14.3) 0.47 
Median SpO2 (IQR) % 95.0 (92.5-96.0) 96.0 (94.0-98.0) 0.09 
Median FiO2 (IQR) 0.21 (0.21-0.24) 0.21 (0.21-0.21) 0.40 
Median PaO2 (IQR) Kpa 5.0 (3.0-9.1) 7.2 (3.8-9.0) 0.30 
Median PaO2:FiO2 ratio (IQR) 20.5 (13.3-32.9) 30.9 (18.1-36.2) 0.09 
Median Respiratory rate (IQR) 
breaths/min 
22.0 (19.0-27.5) 20.0 (17.0-23.0) 0.06 
Median heart rate (IQR) beats/min 86.0 (77.5-99.5) 88.0 (78.0- 107.0) 0.44 
Median Systolic BP (IQR) mmHg 139.5 (117.5-149.0) 135.0 (119.0-152.0) 0.90 
Median duration of illness (IQR) 
days  








Median Hb (IQR) g/dL 12.9 (12.0-13.8) 13.1 (11.6-14.1) 0.46 
Median WCC (IQR) x109/L 7.0 (5.0-8.0) 9.0 (7.0-14.0) 0.08 
Median lymphocyte count (IQR) 
x109/L 
0.8 (0.5-1.2) 1.2 (0.8-1.5) 0.12 
Median platelet count (IQR) x109/L 213.5 (188.5-303.5) 271.0 (186.0-305.0) 0.59 
Median Ferritin (IQR) µg/L 684.7 (206.2-1059.1) 112.3 (49.6-323.6) 0.02 
Median CRP (IQR) mg/L 72.0 (28.5-214.5) 12 (4.0-53.0) 0.004 
Median procalcitonin (IQR) ng/mL 0.2 (0.1-0.6) 0.0 (0.0-0.1) 0.03 
Radiological findings 
    Normal   
    Indeterminate 
    Classic 





















Table 2. Individual and combined diagnostic accuracy of point of care rapid NAAT-
based and antibody tests according to time from initial symptoms. Positivity predictive 
agreement is the percentage of positive test results in samples deemed positive by the 
composite reference standard. Negative predictive agreement is the percentage of negative test 
results in samples deemed negative by the composite reference standard. *43 out of 45 
patients had SureScreen antibody results 
 








SAMBA II NAAT 
   Positive predictive agreement 
   Negative predictive agreement 


















COVIDIX Ig M & IgG   
   Positive predictive agreement 
   Negative predictive agreement 


















SAMBA II NAAT &  
COVIDIX IgM &IgG  
   Positive predictive agreement 






















SureScreen IgM & IgG* 
   Positive predictive agreement 
   Negative predictive agreement 


















SAMBA II NAAT &  
SureScreen IgM & IgG*  
   Positive predictive agreement 
   Negative predictive agreement 





























Table 3: Characteristics of 128 individuals hospitalised with suspected COVID-19 
during implementation of combined POC testing. *testing done on stored serum due to 
fingerprick test failure. NIV- non invasive ventilation; LTOT–long term oxygen therapy; 









Male gender (%) 42.2 
Median age (IQR) yrs 67 (50.8-80.0) 
Median SpO2 (IQR) % 96 (95-97) 
Median fiO2 (IQR) 0.21 (0.21-0.21) 
Maximal Additional Ventilatory Support 
 




Median duration of illness (IQR) days 2.5 (1-7) 
NAAT positive (%) 2 (1.6)  
Neutralisation positive (%, n=101) 8(7.9)  
COVIDIX Healthcare IgG/M positive (%)* 6 (3.9) 
SureScreen IgG/M positive (%)* 6 (3.1) 
Median lymphocyte count (IQR) x109/L 1.3(0.76-1.76) 
Median CRP (IQR) mg/L 46 (15-129) 
Comorbidities  
Cardiovascular disease 44 (34.3) 
Chronic respiratory disease 62 (48.4) 
Chronic kidney disease 11 (8.6) 
Diabetes Mellitus 24 (18.8) 
Immune suppression 13 (10.2) 
Diagnosis 
 
1. Respiratory 61 
2. Cardiovascular 16 
3. Gastrointestinal 13 
4. Genitourinary 7 
5. Other 30 
NEWS score 2 (1-5) 
Chest radiograph findings (n=114) 
 
    Normal  59 
    Indeterminate 31 
    Classic 0 
    Non-COVID-19 24 
CT findings (n=24) 
 
    Normal  3 
    Indeterminate 7 
    Classic 1 
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Figure titles and legends 
Figure 1: Antibody detection for SARS-CoV-2: cross validation of lateral flow 
diagnostic tests (POC antibody tests) with ELISA and SARS-CoV-2 pseudotype virus 
neutralisation assays. A, B. Serum from COVID-19 suspected participants inhibited (n=19) 
(A) or did not inhibit (n=26) (B) SARS-CoV-2 pseudotype virus infection in a neutralisation 
assay. Serum from a healthy donor was used and a negative control. Error bars represent 
SEM. C. Comparison between ELISA and positive/negative results from neutralisation assay. 
n=37, p<0.0001. D. Comparison between ELISA Spike protein reactivity and 
positive/negative POC antibody test results (COVIDIX SARS-CoV-2 IgM/IgG Test). n=38, 
p<0.0001. E. Comparison between EC50 dilution titre from neutralizing assay and 
positive/negative POC antibody test results (COVIDIX SARS-CoV-2 IgM/IgG Test). n=44, 
p=0.0025. F. Comparison between ELISA IgG and positive/negative POC IgG band results 
for SureScreen SARS-CoV-2 IgM/IgG test. n=38, p<0.0001. G. Comparison between EC50 
dilution titre from neutralisation assay and positive/negative SureScreen SARS-CoV-2 
IgM/IgG antibody band test results. n=43, p=0.005. The assays were performed in duplicate. 
 
Figure 2: Venn diagrams comparing positive and negative diagnostic test results in 
hospitalised patients by NAAT (SARS-CoV-2 nucleic acid amplification testing) and point of 
care (POC) antibody testing by A. COVIDIX Healthcare IgM/IgG kit (n=45) and B. 
SureScreen IgM/IgG kit (n=43).  
 








CoV-2, with overall topography of Spike expanded. NTD- N-terminal domain; RBD- 
receptor binding domain; FP- fusion peptide; HR1- heptad repeat 1; HR2- heptad repeat 2; 
TM- transmembrane region; IC- intracellular domain. The aligned sequence of 10 amino 
acids on either side of D614 is shown for 16 participants for whom sequence data were 
available.  A dot represents where the amino acid is unchanged from wildtype, the mutant 
glycine is represented by G. B. Top view of SARS-CoV-2 Spike glycoprotein trimeric 
structure in a closed state, with position 614 in yellow in each protomer. Structure determined 
by cryogenic electron microscopy.  RCSB PDB 6VXX. 
 
Figure 4: Longitudinal antibody responses in patients infected with D614G mutant 
SARS-CoV-2 detected by rapid lateral flow and neutralisation assays. A, D, G. 
An immune-chromatographic lateral flow rapid diagnostic test (POC antibody test -
COVIDIX SARS-CoV-2 IgM IgG Test) on longitudinal samples in individual 
patients detecting SARS-CoV-2 IgM and IgG bands. Band intensities were 
acquired using ChemiDoc MP Imaging System and quantified using Image Lab software. B, 
E, H. SARS-CoV-2 pseudotyped virus neutralisation assay from longitudinal serum samples 
in individual patient examples. The assays were performed in duplicate. Error bars represent 
SEM. C, F, I. Comparison of IgG band intensities from lateral flow rapid diagnostic test with 
EC50 neutralisation titres from SARS-CoV-2 pseudotyped virus neutralisation assay in 
individual patients. Correlations were estimated by linear regression analysis.  
 
Figure 5: Distribution of serum neutralisation activity against SARS-CoV-2 in 
hospitalised patients during implementation phase (A) Neutralisation EC50 dilution titre 
interpreted as positive or negative using a cut off for positive neutralisation of 1:4 dilution 
(B) Neutralisation data for individual patients stratified by POC antibody test result (both 
tests were fully concordant in phase 2). Data points represent reciprocal dilution of serum 
required to inhibit 50% of infection by lentivirus pseudotyped with SARS-CoV-2 Spike 
glycoprotein. The assays were performed in duplicate. Line represents mean and bar 





















Further information should be directed to and will be fulfilled by the Lead Contact, Ravindra 




This study did not generate new unique reagents. 
 
 
Data and Code Availability 
 
Raw anonymised data are available from the lead contact without restriction. 
 
 





The study was conducted in two phases; a clinical validation phase followed by an 
implementation phase. The study participants in phase one were part of the COVIDx trial18, a 
prospective analytical study which compared SAMBA II SARS-CoV-2 point of care test to 
the standard laboratory RT-PCR test for the detection of SARS-CoV-2 in participants 
admitted to Cambridge University Hospitals NHS Foundation Trust (CUH) with a possible 
diagnosis of COVID-19. Consecutive participants were recruited during 12-hour day shifts 
over a duration of 4 weeks from the 6th of April 2020 to the 2nd of May 2020. We recruited 
adults (>16 years old) presenting to the emergency department or acute medical assessment 
unit as a possible case of COVID-19 infection. This included any adult requiring hospital 
admission and who was symptomatic of SARS-CoV-2 infection, demonstrated by clinical or 
radiological findings 18. 45 participants who had available stored sera were included in this 
sub-study and underwent further antibody testing. Phase 2, from July 13th to 27th 2020, 
comprised a service evaluation of clinical practice whereby adults (>16 years old) presenting 








19 infection were included. This included any adult requiring hospital admission and who 
was symptomatic of SARS-CoV-2 infection, demonstrated by clinical or radiological 
findings. 
 
Cell lines  
 
293T cells were cultured in DMEM complete (DMEM supplemented with 100 U/ml 




COVIDx (NCT04326387) was approved by the East of England - Essex Research Ethics 
Committee (REC ref: 20/EE/0109). Serum samples were obtained from patients attending 
Addenbrooke’s Hospital with a suspected or confirmed diagnosis of COVID19. Prospective 
combined point of care testing of suspected COVID-19 cases was done under CUH NHS 








The standard laboratory RT- PCR test, developed by public health England (PHE), targeting 
the RdRp gene was performed on a combined nose/throat swab. This test has an estimated 
limit of detection of 320 copies/ml. In parallel, SAMBA II SARS-CoV-2 testing was 
performed on a combined nose/throat swab and inactivated in a proprietary buffer at the point 
of sampling. SAMBA II SARS-CoV-2 targets 2 genes- Orf1 and the N genes and uses 
nucleic acid sequence based amplification to detect SARS-CoV-2 RNA, with limit of 
detection of 250 copies/ml.31 
 
Pseudotype virus preparation 
Viral vectors were prepared by transfection of 293T cells by using Fugene HD transfection 








of Fugene HD, 1µg of pCAGGS_SARS-CoV-2_Spike or pCDNA∆19Spike-HA, 1ug of 
p8.91 HIV-1 gag-pol expression vector32,33, and 1.5µg of pCSFLW (expressing the firefly 
luciferase reporter gene with the HIV-1 packaging signal). Viral supernatant was collected at 
48 and 72h after transfection, filtered through 0.45um filter and stored at -80˚C. The 50% 
tissue culture infectious dose (TCID50) of SARS-CoV-2 pseudovirus was determined using 
Steady-Glo Luciferase assay system (Promega).  
 
Pseudotype neutralisation assay 
Spike pseudotype assays have been shown to have similar characteristics as neutralisation 
testing using fully infectious wild type SARS-CoV-234.Virus neutralisation assays were 
performed on 293T cell transiently transfected with ACE2 and TMPRSS2 using SARS-CoV-
2 Spike pseudotyped virus expressing luciferase. Pseudovirus was incubated with serial 
dilution of heat inactivated human serum samples from COVID-19 suspected individuals in 
duplicates for 1h at 37˚C. Virus and cell only controls were also included. Then, freshly 
trypsinized 293T ACE2/TMPRSS2 expressing cells were added to each well. Following 48h 
incubation in a 5% CO2 environment at 37°C, the luminescence was measured using Steady-
Glo Luciferase assay system (Promega).  
 
Enzyme-linked immunosorbent assay (ELISA)  
We developed an ELISA targeting the SARS-CoV-2 Spike and N proteins. Trimeric spike 
protein antigen used in the ELISA assays consists of the complete S protein ectodomain with 
a C-terminal extension containing a TEV protease cleavage site, a T4 trimerization foldon 
and a hexa-histidine tag. The S1/S2 cleavage site with amino acid sequence PRRAR was 
replaced with a single Arginine residue and stabilizing Proline mutants were inserted at 
positions 986 and 987. Spike protein was expressed and purified from Expi293 cells (Thermo 
Fisher). N protein consisting of residues 45-365 was initially expressed as a His-TEV-
SUMO-fusion. After Ni-NTA purification, the tag was removed by TEV proteolysis and the 
cleaved tagless protein further purified on Heparin and gel filtration columns.  
The ELISAs were in a stepwise process; a positivity screen was followed by endpoint titre as 
previously described22. Briefly, 96-well EIA/RIA plates (Corning, Sigma) were coated with 
PBS or 0.1µg per well of antigen at 4°C overnight. Coating solution was removed, and wells 
were blocked with 3% skimmed milk prepared in PBS with 0.1% Tween 20 (PBST) at 








diluted to 1:60 or serially diluted by 3-fold, six times in 1% skimmed milk in PBST. 
Blocking solution was aspirated and the diluted sera were added to the plates and incubated 
for 2 hours at ambient temperature. Diluted sera were removed, and plates were washed three 
times with PBST. Goat anti-human IgG secondary antibody-Peroxidase (Fc-specific, Sigma) 
prepared at 1:3,000 in PBST was added and plates were incubated for 1 hour at ambient 
temperature. Plates were washed three times with PBST. ELISAs were developed using 
3,5,3′,5′- tetramethylbenzidine (TMB, ThermoScientific); reactions were stopped after 10 
minutes using 0.16M Sulfuric acid.  
 
COVIDIX 2019 SARS-CoV-2 IgG/IgM Test (COVIDIX Healthcare, Cambridge, UK). 
This colloidal-gold lateral flow immunoassay is designed to detect IgG and IgM to SARS-
CoV-2. The test is CE marked. It was used according to the manufacturer’s instructions. 10µl 
of serum was added to the test well followed by 2 drops of the manufacturer’s proprietary 
buffer. In order to rule out cross reactivity of this test with seasonal coronavirus antibodies 
we tested 19 stored specimens from before 2020, some of which had N and S protein SARS-
CoV-2 cross reactivity (Supplementary table 2).  
 
SureScreen SARS-CoV-2 IgG/IgM Test (SureScreen Diagnostics Ltd, Derby, UK). This 
colloidal-gold lateral flow immunoassay is designed to detect IgG and IgM to SARS-CoV-2. 
It was used according to the manufacturer’s instructions. The test has been CE marked and 
previously validated against a large panel of negative historical controls and in serum from 
confirmed PCR positive COVID-19 cases16. 10µl of serum was added to the test well 
followed by 2 drops of the manufacturer’s proprietary buffer.  
 
Next generation sequencing of SARS-CoV-2 isolates in nose/throat swabs 
Samples with CT values above 33 were sequenced with a multiplex PCR approach according 
to the ARTIC version 2 protocol with version 3 primer set. Amplicons were sequenced using 
MinION flow cells version 9.4.1 (Oxford Nanopore Technologies, Oxford, UK). Genomes 
were assembled as previously described35. The sequences are freely available from GISAID 
EpiCoVTM under accession IDs: EPI_ISL 433757, 433754, 433792, 433850, 433751, 
433778, 433869, 433875, 433874, 433917, 433962, 433956, 434034, 438681, 438711 and 
444331. The submitting laboratory is the COVID-19 Genomics UK (COG-UK) Consortium 









 QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Enzyme-linked immunosorbent assay (ELISA) quantification 
The optical density at 450 nm (OD450) was measured using a Spectramax i3 plate 
reader. The absorbance values for each sample were determined by subtracting OD values 
from uncoated wells.  All data analyses were performed using Prism 8 version 8.4.2 
(GraphPad). An OD cut off of 0.3 was used to define a positive IgG response to full length 
Spike protein. 
 
COVIDIX 2019 nCoV IgG/IgM Test band density 
For quantification of IgG and IgM band density in COVIDIX 2019 nCoV IgG/IgM Test, high 
resolution images of completed POC antibody test cassettes were acquired using ChemiDoc 
MP Imaging System (Bio-Rad) at 20min post-addition of the human serum. Band intensities 
were analysed using Image Lab software (Bio-Rad). 
 
Quantification of neutralisation sensitivity 
The 50% inhibitory dilution (EC50) was defined as the serum dilution at which the relative 
light units (RLUs) were reduced by 50% compared with the virus control wells (virus + cells) 
after subtraction of the background RLUs in the control groups with cells only. The EC50 
values were calculated with non-linear regression, log (inhibitor) vs. normalized response 
using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA). The neutralisation 
assay was positive if the serum achieved at least 50% inhibition at 1 in 3 dilution of the 
SARS-CoV-2 spike protein pseudotyped virus in the neutralisation assay.  The neutralisation 
result was negative if it failed to achieve 50% inhibition at 1 in 3 dilution. 
 
Assessment of neutralisation assay performance 
Four assays detecting IgG to COVID-19 were utilised in this study. 38 of the 45 samples 
were identified as concordant with at least three of the four assays and considered confirmed 
either negative or positive. Against this group of samples validated for content of COVID-19 
IgG, each individual assay was assessed. Neutralisation, ELISA, SureScreen and COVIDIX 
assays gave a correct result in 100%, 97.4%, 92.1% and 86.8%, respectively, justifying the 










The performance of SAMBA II SARS-CoV-2 test and COVIDIX SARS-CoV-2 IgG/IgM 
Test or SureScreen SARS-CoV-2 IgG/IgM Test for diagnosing COVID-19 were calculated 
alone and then in combination along with binomial 95% confidence intervals (CI). A 
composite reference standard was used -  standard lab RT-PCR and a neutralisation assay. 
Descriptive analyses of clinical and demographic data are presented as median and 
interquartile range (IQR) when continuous and as frequency and proportion (%) when 
categorical. The differences in continuous and categorical data were tested using Wilcoxon 
rank sum and Chi-square test respectively. Statistical analysis were conducted using Stata 
(version 13) and GraphPad Prism (version 8), with additional plots generated using GraphPad 
Prism.  Venn diagrams were prepared using Venny36. Structural modelling of location of 
D614G was done using Mol*: D. Sehnal et al (doi:10.2312/molva.20181103). 
 
 
ADDITIONAL RESOURCES  
 

























KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Goat anti-human IgG antibody Sigma Cat# A0170 
Bacterial and Virus Strains  
Biological Samples   
Participants combined nose and throat swab This study N/A 
Participants serum This study N/A 
   
Chemicals, Peptides, and Recombinant Proteins 
SARS-CoV-2 Spike protein  Laboratory of J. Briggs 37 
SARS-CoV-2 N protein Laboratory of J. Nathan N/A 
Critical Commercial Assays 
SAMBA II SARS-CoV-2 test Diagnostics for the real 
World 
Cat# 8500-12 
SARS-CoV-2 RT-PCR in-house test on was performed on 
Qiagen Roto gene platform 
Qiagen N/A 
COVIDIX 20019 SARS-CoV-2 IgG/IgM Test COVIDIX Healthcare Cat# ICOV-402 
SureScreen SARS-CoV-2 IgG/IgM Test  SureScreen Diagnostics  Cat# COVID19 
Deposited Data 
Mapping and structural mapping of D614G was done on S 
protein structure deposited in PDB 
PDB  RCSB PDB 6VXX. 
Sequences of SARS-CoV-2  GISAID EpiCoVTM www.gisaid.org 
Experimental Models: Cell Lines 
Expi293 cells Laboratory of J. Briggs 37 
293T Laboratory of Greg 
Towers 
N/A 
Experimental Models: Organisms/Strains 
Oligonucleotides 








pCDNA∆19Spike-HA Laboratory of P. Lehner N/A 
 
pCSFLW Laboratory of G. Towers N/A 
 








Software and Algorithms 
STATA version 13 STATA https://www.stata.com
/order/download-
details/ 
R 2.6.3 The R project https://www.r-
project.org/ 
Image Lab Bio-Rad N/A 
GraphPad Prism 8 GraphPad Software N/A 
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• Combined rapid antibody + nucleic acid detection correctly diagnoses SARS-CoV-2 
• Rapid antibody tests detect immune responses against SARS-CoV-2 bearing D614G  
• Rapid SARS-CoV-2 antibody tests do not cross react with antibodies to seasonal CoV 
• False positivity in SARS-CoV-2 finger prick blood antibody tests can be very low. 
 
ETOC blurb 
Mlcochova et al. report that combined rapid nucleic acid amplification testing (NAAT) and 
finger prick blood antibody tests can substantially improve diagnosis of COVID-19 as 
compared to NAAT alone and are able to detect the SARS-CoV-2 Spike D614G variant that 
dominates the pandemic.  
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